Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.80
ALKS's Cash to Debt is ranked lower than
73% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ALKS: 1.80 )
Ranked among companies with meaningful Cash to Debt only.
ALKS' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 1.53 Max: No Debt
Current: 1.8
Equity to Asset 0.71
ALKS's Equity to Asset is ranked higher than
53% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ALKS: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
ALKS' s Equity to Asset Range Over the Past 10 Years
Min: -0.15  Med: 0.61 Max: 0.9
Current: 0.71
-0.15
0.9
F-Score: 3
Z-Score: 6.45
M-Score: -3.12
WACC vs ROIC
18.08%
-27.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -43.90
ALKS's Operating margin (%) is ranked higher than
54% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. ALKS: -43.90 )
Ranked among companies with meaningful Operating margin (%) only.
ALKS' s Operating margin (%) Range Over the Past 10 Years
Min: -35.7  Med: -7.62 Max: 41.29
Current: -43.9
-35.7
41.29
Net-margin (%) -43.91
ALKS's Net-margin (%) is ranked higher than
54% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. ALKS: -43.91 )
Ranked among companies with meaningful Net-margin (%) only.
ALKS' s Net-margin (%) Range Over the Past 10 Years
Min: -36.15  Med: -1.29 Max: 69.37
Current: -43.91
-36.15
69.37
ROE (%) -20.24
ALKS's ROE (%) is ranked higher than
57% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. ALKS: -20.24 )
Ranked among companies with meaningful ROE (%) only.
ALKS' s ROE (%) Range Over the Past 10 Years
Min: -18.25  Med: 0.11 Max: 65.64
Current: -20.24
-18.25
65.64
ROA (%) -14.62
ALKS's ROA (%) is ranked higher than
61% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. ALKS: -14.62 )
Ranked among companies with meaningful ROA (%) only.
ALKS' s ROA (%) Range Over the Past 10 Years
Min: -12.04  Med: -0.42 Max: 27.26
Current: -14.62
-12.04
27.26
ROC (Joel Greenblatt) (%) -74.82
ALKS's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ALKS: -74.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALKS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -60.91  Med: 6.41 Max: 131.93
Current: -74.82
-60.91
131.93
Revenue Growth (3Y)(%) 7.40
ALKS's Revenue Growth (3Y)(%) is ranked higher than
54% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ALKS: 7.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALKS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.1  Med: 13.90 Max: 69.6
Current: 7.4
-22.1
69.6
EPS Growth (3Y)(%) 15.40
ALKS's EPS Growth (3Y)(%) is ranked higher than
73% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ALKS: 15.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALKS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.2  Med: 16.00 Max: 226.4
Current: 15.4
-24.2
226.4
» ALKS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

ALKS Guru Trades in Q2 2015

Jim Simons 229,286 sh (+15.40%)
Pioneer Investments 287,959 sh (+14.19%)
Murray Stahl 25,000 sh (unchged)
Vanguard Health Care Fund 6,229,583 sh (unchged)
Ken Fisher 107,164 sh (unchged)
Jeff Auxier 26,851 sh (-0.37%)
» More
Q3 2015

ALKS Guru Trades in Q3 2015

George Soros 7,900 sh (New)
Ken Fisher 119,920 sh (+11.90%)
Vanguard Health Care Fund 6,879,583 sh (+10.43%)
Pioneer Investments 300,413 sh (+4.32%)
Jeff Auxier 26,851 sh (unchged)
Murray Stahl 25,000 sh (unchged)
Jim Simons Sold Out
» More
Q4 2015

ALKS Guru Trades in Q4 2015

Jim Simons 26,286 sh (New)
Paul Tudor Jones 6,782 sh (New)
Ken Fisher 120,327 sh (+0.34%)
Murray Stahl 25,000 sh (unchged)
Jeff Auxier 26,851 sh (unchged)
Vanguard Health Care Fund 6,851,996 sh (-0.40%)
Pioneer Investments 208,726 sh (-30.52%)
George Soros 3,400 sh (-56.96%)
» More
Q1 2016

ALKS Guru Trades in Q1 2016

Murray Stahl 25,000 sh (unchged)
Ken Fisher 120,297 sh (-0.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ALKS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 133.33
ALKS's Forward P/E is ranked lower than
91% of the 85 Companies
in the Global Biotechnology industry.

( Industry Median: 17.79 vs. ALKS: 133.33 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.75
ALKS's P/B is ranked lower than
64% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ALKS: 4.75 )
Ranked among companies with meaningful P/B only.
ALKS' s P/B Range Over the Past 10 Years
Min: 1.66  Med: 4.21 Max: 412.83
Current: 4.75
1.66
412.83
P/S 9.53
ALKS's P/S is ranked higher than
55% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. ALKS: 9.53 )
Ranked among companies with meaningful P/S only.
ALKS' s P/S Range Over the Past 10 Years
Min: 2.21  Med: 7.08 Max: 18.81
Current: 9.53
2.21
18.81
Current Ratio 3.74
ALKS's Current Ratio is ranked lower than
57% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ALKS: 3.74 )
Ranked among companies with meaningful Current Ratio only.
ALKS' s Current Ratio Range Over the Past 10 Years
Min: 2.01  Med: 6.22 Max: 15.4
Current: 3.74
2.01
15.4
Quick Ratio 3.54
ALKS's Quick Ratio is ranked lower than
56% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ALKS: 3.54 )
Ranked among companies with meaningful Quick Ratio only.
ALKS' s Quick Ratio Range Over the Past 10 Years
Min: 1.95  Med: 5.99 Max: 15.4
Current: 3.54
1.95
15.4
Days Inventory 119.79
ALKS's Days Inventory is ranked higher than
51% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. ALKS: 119.79 )
Ranked among companies with meaningful Days Inventory only.
ALKS' s Days Inventory Range Over the Past 10 Years
Min: 86.09  Med: 110.47 Max: 166.33
Current: 119.79
86.09
166.33
Days Sales Outstanding 81.80
ALKS's Days Sales Outstanding is ranked lower than
61% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. ALKS: 81.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALKS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.46  Med: 82.14 Max: 90.32
Current: 81.8
27.46
90.32
Days Payable 95.08
ALKS's Days Payable is ranked higher than
63% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. ALKS: 95.08 )
Ranked among companies with meaningful Days Payable only.
ALKS' s Days Payable Range Over the Past 10 Years
Min: 39.15  Med: 65.98 Max: 561.6
Current: 95.08
39.15
561.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 63.10
ALKS's Price/Net Cash is ranked lower than
93% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. ALKS: 63.10 )
Ranked among companies with meaningful Price/Net Cash only.
ALKS' s Price/Net Cash Range Over the Past 10 Years
Min: 3.39  Med: 12.40 Max: 115.47
Current: 63.1
3.39
115.47
Price/Net Current Asset Value 19.49
ALKS's Price/Net Current Asset Value is ranked lower than
82% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. ALKS: 19.49 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALKS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.39  Med: 11.24 Max: 343
Current: 19.49
2.39
343
Price/Tangible Book 7.43
ALKS's Price/Tangible Book is ranked lower than
69% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ALKS: 7.43 )
Ranked among companies with meaningful Price/Tangible Book only.
ALKS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.8  Med: 9.69 Max: 365.22
Current: 7.43
1.8
365.22
Price/Projected FCF 6.51
ALKS's Price/Projected FCF is ranked lower than
64% of the 176 Companies
in the Global Biotechnology industry.

( Industry Median: 3.66 vs. ALKS: 6.51 )
Ranked among companies with meaningful Price/Projected FCF only.
ALKS' s Price/Projected FCF Range Over the Past 10 Years
Min: 2  Med: 3.87 Max: 20.95
Current: 6.51
2
20.95
Price/Median PS Value 1.35
ALKS's Price/Median PS Value is ranked lower than
71% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. ALKS: 1.35 )
Ranked among companies with meaningful Price/Median PS Value only.
ALKS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 1.69 Max: 14.41
Current: 1.35
0.42
14.41
Earnings Yield (Greenblatt) (%) -4.50
ALKS's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. ALKS: -4.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALKS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 2.35 Max: 53.4
Current: -4.5
0.1
53.4

More Statistics

Revenue(Mil) $624
EPS $ -1.82
Beta2.26
Short Percentage of Float7.13%
52-Week Range $27.14 - 80.71
Shares Outstanding(Mil)151.17

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 718 846 1,000
EPS($) -0.31 0.30 0.65
EPS without NRI($) -0.31 0.30 0.65

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:8AK.Germany,
Alkermes PLC is a biotechnology company. The Company is engaged in developing, manufacturing and commercializing medicines. The Company has a portfolio of commercial drug products and a clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression. The Company's products include CODAS, IPDAS, LinkeRx, MXDAS, NanoCrystal, SODAS, VERELAN and VIVITROL.
» More Articles for NAS:ALKS

Headlines

Articles On GuruFocus.com
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs Jan 04 2016 
Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
Opportunistic Coat-tailing Jan 05 2010 
Weekly Guru Bargains Highlights: Coinstar Inc, Fair Isaac Corp, Alkermes Inc, American International Dec 12 2009 

More From Other Websites
Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss Apr 29 2016
Edited Transcript of ALKS earnings conference call or presentation 28-Apr-16 12:30pm GMT Apr 28 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes reports 1Q loss Apr 28 2016
Alkermes Plc Earnings Call scheduled for 8:30 am ET today Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Q1 2016 Alkermes Plc Earnings Release - Before Market Open Apr 28 2016
ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes plc Reports First Quarter 2016 Financial Results Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes Announces Plan to Initiate Second Clinical Trial of ALKS 7119 Based on Preliminary Phase 1... Apr 28 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Alkermes to Host Conference Call to Discuss First Quarter 2016 Financial Results Apr 21 2016
Stalking a Speculative Trade in Alkermes Apr 14 2016
Alkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : April 1, 2016 Apr 01 2016
Study on Extended-Release Naltrexone in Opioid-Dependent Patients Involved in Criminal Justice... Mar 31 2016
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research... Mar 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK